3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Uterine Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Breast Cancer
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Neutropenia
1
Neoplasms, Unknown Primary
1
Neoplasms
1
NSCLC
1
Melanoma
1
Malnutrition
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
38
Fluorouracil
37
Radiotherapy
33
Oxaliplatin
23
Paclitaxel
20
Irinotecan
18
Leucovorin
17
Docetaxel
17
Capecitabine
10
Neoadjuvant Therapy
9
Surgical Procedures, Operative
8
Cetuximab
8
Chemotherapy, Adjuvant
7
Radiation
6
Carboplatin
6
Immunohistochemistry
5
Erlotinib Hydrochloride
5
Biopsy
5
Magnetic Resonance Spectroscopy
4
Gene Expression Profiling
4
Folfox protocol
4
Epirubicin
4
Drug Therapy
4
pembrolizumab
3
Trastuzumab
3
Microarray Analysis
3
Gefitinib
3
Fluorodeoxyglucose F18
3
Endoscopy, Digestive System
3
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma Of Esophagus
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled